Diabetic dyslipidemia or ‘diabetes lipidus’?

Diabetes mellitus is one of the most important risk factors for cardiovascular diseases. The results of several studies have shown that achieving satisfactory glucoregulation results in a significant reduction in the incidence of microvascular and macrovascular complications, and cardiovascular mortality. However, the risk of the development of cardiovascular diseases is markedly increased in the presence of dyslipoproteinemia. Research has shown that hyperglycemia not only causes apoptosis of β-cells in the islets of Langerhans (glucotoxicity) but also determines the degree of accumulation of oxidized LDLs. On the other hand, dyslipoproteinemia itself has a toxic effect on β-cells, but only in the presence of increased blood glucose levels, thus increasing the risk of the development of cardiovascular diseases exponentially. As diabetes and the lipid metabolism disorder can be neither scrutinized nor treated separately, the authors query whether ‘diabetes lipidus’ would be a more appropriate term.

[1]  Ž. Reiner Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & clinical pharmacology.

[2]  J. Born,et al.  Enhancing influence of intranasal interleukin‐6 on slowwave activity and memory consolidation during sleep , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Ž. Reiner How to improve cardiovascular diseases prevention in Europe? , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[5]  M. Cooper,et al.  UKPDS and the legacy effect. , 2008, The New England journal of medicine.

[6]  A. Jenkins,et al.  Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications , 2008, Diabetes Care.

[7]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[8]  Jian-Dong Li,et al.  Extracellular Signal-Regulated Kinase 5 SUMOylation Antagonizes Shear Stress–Induced Antiinflammatory Response and Endothelial Nitric Oxide Synthase Expression in Endothelial Cells , 2008, Circulation research.

[9]  Ž. Reiner,et al.  The burden of hyperlipidaemia and diabetes in cardiovascular diseases , 2007, Fundamental & clinical pharmacology.

[10]  Ž. Reiner,et al.  Clinical Study on the Effect of Simvastatin on Paraoxonase Activity , 2007, Arzneimittelforschung.

[11]  M. Chapman Metabolic syndrome and type 2 diabetes: lipid and physiological consequences , 2007, Diabetes & vascular disease research.

[12]  P. Durrington,et al.  Lipids and their metabolism , 2007 .

[13]  T. M. Lewin,et al.  Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[14]  D. Mikhailidis,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.

[15]  K. Channon,et al.  Endothelial Nox2 Overexpression Potentiates Vascular Oxidative Stress and Hemodynamic Response to Angiotensin II: Studies in Endothelial-Targeted Nox2 Transgenic Mice , 2006, Circulation research.

[16]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[17]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[18]  D. Harrison,et al.  Oxidant stress—a major cause of reduced endothelial nitric oxide availability in cardiovascular disease , 2006, European Journal of Clinical Pharmacology.

[19]  W. Benzer,et al.  Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? , 2005, Diabetes care.

[20]  H. Ginsberg,et al.  Regulation of plasma triglycerides in insulin resistance and diabetes. , 2005, Archives of medical research.

[21]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[22]  R. Krauss Lipids and lipoproteins in patients with type 2 diabetes. , 2004, Diabetes care.

[23]  B. Berk,et al.  Big Mitogen-Activated Protein Kinase (BMK1)/ERK5 Protects Endothelial Cells From Apoptosis , 2004, Circulation research.

[24]  D. Betteridge,et al.  Clinicians' Guide to Lipids and Coronary Heart Disease , 2003 .

[25]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .

[26]  G. Lewis,et al.  Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[27]  R. Robertson,et al.  Minireview: Secondary β-Cell Failure in Type 2 Diabetes-A Convergence of Glucotoxicity and Lipotoxicity. , 2002, Endocrinology.

[28]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[29]  Timothy McCaffrey,et al.  A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation , 2001, Nature Medicine.

[30]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[31]  I. Goldberg Diabetic Dyslipidemia: Causes and Consequences , 2001 .

[32]  A. Gotto,et al.  Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, European heart journal.

[33]  D. Rudy,et al.  Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance , 2000, The Journal of Biological Chemistry.

[34]  B. Sobel,et al.  A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering , 1999, Journal of cardiovascular risk.

[35]  Betteridge Diabetic dyslipidaemia , 1999, European journal of clinical investigation.

[36]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[37]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[38]  L. Wilhelmsen,et al.  Diabetes and Long-Term Risk of Mortality From Coronary and Other Causes in Middle-Aged Swedish Men: A general population study , 1998, Diabetes Care.

[39]  S. Lillioja,et al.  Skeletal Muscle Triglyceride Levels Are Inversely Related to Insulin Action , 1997, Diabetes.

[40]  J. Abe,et al.  Big Mitogen-activated Protein Kinase 1 (BMK1) Is a Redox-sensitive Kinase* , 1996, The Journal of Biological Chemistry.

[41]  G. Lewis,et al.  Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state , 1996, Diabetes Care.

[42]  P. Maloney,et al.  Exchange of Aspartate and Alanine , 1996, The Journal of Biological Chemistry.

[43]  D. Stafforini,et al.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.

[44]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[45]  R. Krauss Heterogeneity of plasma low‐density lipoproteins and atherosclerosis risk , 1994, Current opinion in lipidology.

[46]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[47]  P. Gambert,et al.  Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetes. , 1992, Diabete & metabolisme.

[48]  H. Ginsberg,et al.  Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. , 1991, The Journal of biological chemistry.

[49]  P. Savage,et al.  The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. , 1990, American journal of epidemiology.

[50]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[51]  P. Strålfors,et al.  Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. , 1989, European journal of biochemistry.

[52]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[53]  G. Roglić,et al.  Mortality attributable to diabetes: estimates for the year 2010. , 2010, Diabetes research and clinical practice.

[54]  S. Schinner Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[55]  L. Ruilope,et al.  The ADVANCE Trial , 2009, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[56]  J. Bigger,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group , 2008 .

[57]  K. Channon,et al.  Endothelial Nox 2 Overexpression Potentiates Vascular Oxidative Stress and Hemodynamic Response to Angiotensin II Studies in Endothelial-Targeted Nox 2 Transgenic Mice , 2007 .

[58]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[59]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[60]  B. Hoogwerf,et al.  Nutrition principles and recommendations in diabetes. , 2004, Diabetes care.

[61]  S. Haffner Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.

[62]  J. McGarry Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[63]  G. Lewis,et al.  Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. , 1995, The Journal of clinical investigation.

[64]  P. Knight,et al.  Epidemiology and Pathophysiology , 1990 .

[65]  J. Canivet,et al.  [Secondary hyperlipidemia]. , 1965, La Revue du praticien.

[66]  SISTER MARY HILAIRE The diabetic patient. , 1948, Hospital progress.